Despite its theoretical plausibility, however, disparate outcomes of treatments are often observed in patients treated with repurposed therapies in a histotype-dependent manner (e.g., distinct response patterns were seen in non-melanoma BRAF V600E cancers treated with vemurafenib44). Here, BRAF is linked to melanoma.